Literature DB >> 22020400

Successful treatment of mast cell sarcoma of the uterus with imatinib.

Hong Bing Ma1, Xia Xu, Wei Ping Liu, Hong Chang, Fan Zeng, Yu Chun Wang.   

Abstract

Mast cell sarcoma is a rare disease characterized by localized, but destructive and rapid, growth of the tumor, high risk of distant metastasis, possibility of a leukemic phase, and poor prognosis. We report successful treatment of uterine mast cell sarcoma with imatinib in a 39-year-old woman who presented with abdominal distention and massive ascites. Routine treatment, such as combined chemotherapy, had little effect. We administered imatinib to the patient and achieved a good response in the absence of c-kit mutation, BCR/ABL, and FIP1L1-PDGFRα. Our results indicate that imatinib is of potential use in the treatment of mast cell sarcoma.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22020400     DOI: 10.1007/s12185-011-0952-2

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  15 in total

1.  [Systemic mastocytosis without the typical mutation of codon 816 successfully treated with imatinib].

Authors:  Yasuo Hirayama; Yuich Konuma; Kyuhei Kohda; Masakatsu Ando; Masahiko Obata; Yoshinori Ueno; Yutaka Sasagawa; Yuko Wada; Sayaka Shirao
Journal:  Nihon Naika Gakkai Zasshi       Date:  2008-10-10

2.  Novel germline mutation of KIT associated with familial gastrointestinal stromal tumors and mastocytosis.

Authors:  Karin Hartmann; Eva Wardelmann; Yongsheng Ma; Sabine Merkelbach-Bruse; Liane M Preussner; Carla Woolery; Stephan E Baldus; Thomas Heinicke; Juergen Thiele; Reinhard Buettner; B Jack Longley
Journal:  Gastroenterology       Date:  2005-09       Impact factor: 22.682

Review 3.  Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy.

Authors:  B J Longley; M J Reguera; Y Ma
Journal:  Leuk Res       Date:  2001-07       Impact factor: 3.156

4.  Mast cell sarcoma with tissue eosinophilia arising in the ascending colon.

Authors:  M Kojima; S Nakamura; H Itoh; Y Ohno; N Masawa; T Joshita; T Suchi
Journal:  Mod Pathol       Date:  1999-07       Impact factor: 7.842

5.  Mast-cell sarcoma of the tibia.

Authors:  Luka Brcić; Lovorka Batelja Vuletić; Jasminka Stepan; Aleksandra Bonevski; Gordana Jakovljević; Slavko Gasparov; Ksenija Marjanović; Sven Seiwerth
Journal:  J Clin Pathol       Date:  2007-04       Impact factor: 3.411

6.  Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases.

Authors:  Michael C Heinrich; Heikki Joensuu; George D Demetri; Christopher L Corless; Jane Apperley; Jonathan A Fletcher; Denis Soulieres; Stephan Dirnhofer; Amy Harlow; Ajia Town; Arin McKinley; Shane G Supple; John Seymour; Lilla Di Scala; Allan van Oosterom; Richard Herrmann; Zariana Nikolova; And Grant McArthur
Journal:  Clin Cancer Res       Date:  2008-05-01       Impact factor: 12.531

7.  Successful treatment of progressive cutaneous mastocytosis with imatinib in a 2-year-old boy carrying a somatic KIT mutation.

Authors:  Karl M Hoffmann; Andrea Moser; Peter Lohse; Andreas Winkler; Barbara Binder; Petra Sovinz; Herwig Lackner; Wolfgang Schwinger; Martin Benesch; Christian Urban
Journal:  Blood       Date:  2008-06-20       Impact factor: 22.113

8.  A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib.

Authors:  Cem Akin; Gerard Fumo; Akif S Yavuz; Peter E Lipsky; Len Neckers; Dean D Metcalfe
Journal:  Blood       Date:  2003-12-24       Impact factor: 22.113

Review 9.  Mastocytosis: state of the art.

Authors:  Hans-Peter Horny; Karl Sotlar; Peter Valent
Journal:  Pathobiology       Date:  2007       Impact factor: 4.342

10.  Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis.

Authors:  Arturo Vega-Ruiz; Jorge E Cortes; Matjaz Sever; Taghi Manshouri; Alfonso Quintás-Cardama; Raja Luthra; Hagop M Kantarjian; Srdan Verstovsek
Journal:  Leuk Res       Date:  2009-02-03       Impact factor: 3.156

View more
  4 in total

1.  Mast cell sarcoma of the sternum, clonally related to an antecedent germ cell tumor with a novel D579del KIT mutation.

Authors:  Atsushi Yamashita; Tsuyoshi Saito; Keisuke Akaike; Atsushi Arakawa; Akihiko Yoshida; Kentaro Kikuchi; Masahiko Sugitani; Takashi Yao
Journal:  Virchows Arch       Date:  2017-02-24       Impact factor: 4.064

2.  Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature.

Authors:  Iván Alvarez-Twose; Almudena Matito; José Mário Morgado; Laura Sánchez-Muñoz; María Jara-Acevedo; Andrés García-Montero; Andrea Mayado; Carolina Caldas; Cristina Teodósio; Javier Ignacio Muñoz-González; Manuela Mollejo; Luis Escribano; Alberto Orfao
Journal:  Oncotarget       Date:  2016-07-19

Review 3.  Mast cell sarcoma: new cases and literature review.

Authors:  Jilliana Monnier; Sophie Georgin-Lavialle; Danielle Canioni; Ludovic Lhermitte; Michael Soussan; Michel Arock; Julie Bruneau; Patrice Dubreuil; Christine Bodemer; Marie-Olivia Chandesris; Olivier Lortholary; Olivier Hermine; Gandhi Damaj
Journal:  Oncotarget       Date:  2016-10-04

4.  Case report of a clinically indolent but morphologically high-grade cutaneous mast cell tumor in an adult: Atypical cutaneous mastocytoma or mast cell sarcoma?

Authors:  Claire L W Wardle; J Marja Oldhoff; Arjan Diepstra; Peter Valent; Hans-Peter Horny; Hanneke N G Oude Elberink; Philip M Kluin; Gilles F H Diercks
Journal:  J Cutan Pathol       Date:  2021-07-02       Impact factor: 1.587

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.